Alphatec (ATEC) Q1 2026 earnings review
Volume Engine Purrs, but EOS Miss and Mix Shifts Spoil the Quarter
Alphatec delivered an impressive 21% surge in surgical volumes driven by a 23% jump in new surgeon users. However, total revenue growth decelerated to 14% ($192M) as the EOS imaging segment stumbled badly, forcing an $8M full-year guidance cut. Adding to the top-line noise, surgical revenue per procedure declined 3% YoY, contradicting the company's historical 'convoyed sales' narrative. Despite the revenue miss, operating leverage remains exceptionally strong: Adjusted EBITDA margin expanded 460 basis points to 11%, and a new debt facility will save $6M in annual interest. The core adoption engine is healthy, but execution missteps in capital equipment and emerging margin mix pressures warrant close monitoring.
🐂 Bull Case
A 23% year-over-year increase in net new surgeon users proves that Alphatec's procedural approach continues to take significant market share from legacy competitors.
The company drove a 45% drop-through on incremental revenue, expanding adjusted EBITDA by 97% year-over-year. The new debt refinancing extends maturities to 2031 and structurally lowers interest expenses.
🐻 Bear Case
EOS revenue dropped 18% YoY to $14M, leading management to slash FY26 EOS guidance by $8M. Relying on capital equipment installations for growth introduces lumpiness and execution risk.
A 3% decline in revenue per procedure, driven by cervical mix and lower biologics attachment, breaks the bull thesis that ATEC will continuously capture more revenue per surgery.
⚖️ Verdict: ⚪
Neutral. The underlying surgical volume growth and profit margin expansion are undeniably strong, but the sudden capital equipment miss, guidance cut, and negative price mix create near-term friction for the stock.
Key Themes
EOS Execution Decelerating
EOS revenue came in at just $14M, down $3M from a year ago. Management cited installation timing and weak sales execution, forcing them to bolster the downstream marketing and sales team. As a result, FY26 EOS guidance was cut from $85M to $77M. While management insists the long-term thesis is intact, this represents a sudden break in the ecosystem growth narrative.
Revenue Per Case Reversing
Surgical revenue per case declined 3% year-over-year. Management attributed this to a higher mix of cervical procedures (which carry lower ASPs), strong international growth, and lower-than-expected biologics attachment (38%). This metric directly contradicts management's long-standing 'convoyed sales' narrative, which historically promised increasing revenue per case as surgeons adopted more of the ATEC portfolio.
Surgical Volume Engine Stable and Strong
The core surgical business remains highly robust. Procedural volumes grew 21% year-over-year, fueled by a 23% increase in net new surgeon users. Lateral, ALIF, and cervical core procedural ASPs were actually up 2%, 4%, and 8% respectively, showing that where ATEC distinguishes itself clinically, it maintains pricing power.
Significant Operating Leverage Accelerating
Despite top-line turbulence, profitability continues to scale beautifully. Adjusted EBITDA grew 97% year-over-year to $21 million. SG&A improved by 420 basis points as a percentage of revenue, and the company achieved a 45% drop-through on the incremental revenue dollar. The company is proving it can self-fund its rapid growth.
Debt Refinancing Structurally Lowers Costs
ATEC replaced its previous term loan with a new syndicated bank facility (Term Loan A and revolver) led by JPMorgan. This extends maturities to 2031, reduces the interest rate to SOFR + 275 bps, and will save the company over $6M annually in cash interest expense—a major positive for future free cash flow generation.
Weather and Seasonality Excuses
Management blamed part of the Q1 softness on late January FedEx constraints and Northeast storms, noting a softer exit in March. While April reportedly rebounded, citing weather as a top-line headwind is typically a red flag for high-multiple growth stocks and warrants strict monitoring in Q2.
Other KPIs
Reversing from positive cash generation in late 2025, but represents a $44 million improvement compared to the $55 million burned in Q1 2025. The cash use was primarily driven by strategic investments of $33M in inventory and instruments to support the 20%+ surgeon adoption growth. Trailing twelve-month FCF remains positive at $7 million.
Accelerating. Despite the capital sales miss in the quarter, the underlying installed base of Edge units grew 39%, and the number of EOS Insight accounts more than doubled. Management noted a ~30% revenue lift per surgeon after Insight adoption, validating the long-term pull-through strategy if they can fix the near-term capital installation lumpiness.
Guidance
Decelerating. Lowered from prior guidance of $890 million. This implies roughly 15% year-over-year growth, down from the 25% growth achieved in FY25. The entire $8M cut is attributable to the EOS segment execution issues.
Stable. Reiterated from prior guidance, representing 17% year-over-year growth. Management expects high-teens volume growth with flat revenue per case for the full year, implying they expect the Q1 mix headwinds to neutralize.
Decelerating. Cut significantly from the prior $85 million expectation. At $77 million, the EOS business will essentially be flat compared to the $77.2 million generated in FY25, indicating a complete stall in capital equipment growth for the year.
Stable. Maintained despite the $8 million revenue cut, which reflects immense confidence in operating leverage and cost controls. Represents a 15% margin, expanding significantly from the 12.2% margin in FY25.
Key Questions
Biologics Attachment Rebound
Revenue per procedure dropped 3% largely due to lower biologics attachment (38%). What specific sales execution changes are being made to drive this back up, and how much of this is reliant on the pending TheraDaptive product launch?
EOS Turnaround Visibility
With FY26 EOS guidance cut by $8M due to installation and sales execution issues, what leading indicators (order book, site surveys) give you confidence that this is a near-term hiccup rather than a structural ceiling on capital appetite from hospitals?
International Mix Pressures
Strong international growth was cited as a margin and ASP headwind. As the international footprint expands, how will this structurally alter the company's long-term gross margin profile?